Citation: Kel. Mccoll et Ls. Murray, Testing for Helicobacter pylori in dyspeptic patients - Authors' strategy would leave many patients with ulcer uncured, BR MED J, 323(7320), 2001, pp. 1067-1067
Authors:
El-Omar, EM
Oien, K
Murray, LS
El-Nujumi, A
Wirz, A
Gillen, D
Williams, C
Fullarton, G
McColl, KEL
Citation: Em. El-omar et al., Increased prevalence of precancerous changes in relatives of gastric cancer patients: Critical role of H-pylori, GASTROENTY, 118(1), 2000, pp. 22-30
Authors:
Vasey, PA
Kaye, SB
Morrison, R
Twelves, C
Wilson, P
Duncan, R
Thomson, AH
Murray, LS
Hilditch, TE
Murray, T
Burtles, S
Fraier, D
Frigerio, E
Cassidy, J
Citation: Pa. Vasey et al., Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents - Drug-polymer conjugates, CLIN CANC R, 5(1), 1999, pp. 83-94
Authors:
Lever, AF
Beevers, DG
Hole, DJ
Isles, CG
Meredith, PA
Murray, LS
McInnes, GT
Reid, JL
Citation: Af. Lever et al., Mortality amongst patients of the Glasgow Blood Pressure Clinic was high in the 1970s and 80s but has fallen since, why?, CLIN EXP HY, 21(5-6), 1999, pp. 553-562
Authors:
Hood, S
Birnie, D
Murray, LS
MacIntyre, PD
Hillis, WS
Citation: S. Hood et al., Changes in systolic time intervals - a non-invasive marker for the haemodynamic effects of sumatriptan, BR J CL PH, 48(3), 1999, pp. 331-335
Authors:
Hood, S
Birnie, D
Swan, L
Murray, LS
Whitehouse, H
Winter, P
Hillis, WS
Citation: S. Hood et al., Effects of subcutaneous naratriptan on systemic and pulmonary haemodynamics and coronary artery diameter in humans, J CARDIO PH, 34(1), 1999, pp. 89-94
Authors:
Thomson, AH
Vasey, PA
Murray, LS
Cassidy, J
Fraier, D
Frigerio, E
Twelves, C
Citation: Ah. Thomson et al., Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours, BR J CANC, 81(1), 1999, pp. 99-107